The University of Rochester has been identified by the journal Nature Biotechnology as one of the top 10 universities in the nation for the impact of its life sciences research.
“This recognition reflects not only the University’s success in attracting federal research funding, but our ability to translate this research into new ideas and technologies that stimulate economic activity and will ultimately improve lives,” said Stephen Dewhurst, Ph.D., vice dean for Research at the University of Rochester School of Medicine and Dentistry. “It is a testament to the exceptional quality of our scientists and more evidence that our faculty continue to outperform their peers when it comes to the impact of our scientific innovation.”
They started with 6,932 applications from 96 countries and all 50 states. On 30 October 2014, the 11 finalists pitched their business plans to the judges.
And the results are . . .
PharmAdva LLC, a medical device manufacturer, has been approved to participate in the START-UP NY economic development program. The company will locate in High Tech Rochester’s (HTR) Lennox Tech Enterprise Center in Henrietta.
Applications for HTR’s Pre-Seed Workshop (early this November) are being accepted through 24 October. Sign up here: http://htr.org/pre-seed-workshop-application.
In addition to teams, the PSW is looking for Idea Champions. An Idea Champion is someone who works with a workshop team to explore opportunities in an idea or invention.
The fall 2014 round of the Technology Development Fund (TDF) has started. The TDF awards winning applications from faculty, staff, or students up to $100,000 to develop their technology to a commercial endpoint. A submitted invention disclosure to UR Ventures is required for an application. Pre-proposals are due October 15th and can be submitted to Omar Bakht. Learn more at www.rochester.edu/tdf.
As of Wednesday, 17 September 2014 UR Ventures has moved to a new location in the Saunders Research Building. We have kept our mailing address, all of our phone numbers, and e-mail addresses. The only difference is our physical location — SRB suite B360. The transition is scheduled to disrupt our operations for no more than a few hours on the morning of the 17th. We’ll be back in action and ready to respond to all of your intellectual property and technology commercialization needs as soon as possible.
Researchers at the University of Rochester Medical Center and University of Nebraska Medical Center have received a $3.4 million grant from the National Institutes of Health to study an experimental drug combination that appears to rid white blood cells of HIV and keep the infection in check for long periods. While current HIV treatments involve pills that are taken daily, the experimental drugs’ long-lasting effects suggest the possibility of an HIV treatment that could be administered monthly, or perhaps a few times a year.
Rochester Business Journal
12 August 2014
The Entrepreneurs Network is soliciting applications for its 17th class, with sessions to begin next month.
The class will meet monthly at High Tech Rochester Inc. in Henrietta and other venues in the Rochester area beginning Sept. 18 and ending in December, officials said.
The class is limited to 15 members. The application deadline is Sept. 5. Upon acceptance, members pay an all-inclusive fee of $350.
Experiment measures millions of quantum trajectories to predict ‘most likely’ route
As a quantum state collapses from a quantum superposition to a classical state or a different superposition, it will follow a path known as a quantum trajectory. For each start and end state there is an optimal or “most likely” path, but it is not as easy to predict the path or track it experimentally as a straight-line between two points would be in our everyday, classical world.